Roche says entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Roche Holding said its effort to expand in gene therapy via the $4.3 billion takeover of Spark Therapeutics remained on track despite failing to get enough votes to clinch the deal and as U.S. regulators continued scrutinizing it......»»

Roche Holding has extended until May 2 its $4.3 billion offer for U.S. gene therapy specialist Spark Therapeutics, the Swiss drugmaker said after getting only 29.4 percent of Spark's shares in a tender originally due to end on Wednesday......»»

Roche and Biogen are spending big bucks on gene therapy biotech stocks......»»

ReutersRoche takes on Loxo, Bayer in gene-defined cancer classReutersMUNICH (Reuters) - Roche'.....»»

The FDA accepts Roche's (RHHBY) BLA for polatuzumab vedotin and NDAs for entrectinib, an.....»»

Roche Holding AG will buy Spark Therapeutics Inc. for $4.8 billion, a deal that will give the Swiss drugmaker one of the first-ever therapies to treat, and potentially cure, a disease by providing a fix for a patient’s defective genes......»»

Purchasing Philadelphia-based Spark will help Roche to compete with Basel-based neighbor Novartis AG in developing the new area of medicine .....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Purchasing Philadelphia-based Spark will help Roche to compete with Basel-based neighbor Novartis AG in developing the new area of medicine .....»»

Roche Holding AG is to buy U.S.-based Spark Therapeutics in a $4.3 billion deal that will give the Swiss drugmaker a foothold in gene therapy. Ciara Lee reports......»»

Roche Holdings AG Basel ADR (OTC: RHHBY)'s announcement regarding an agreement to acquire gene therapy company Spark Therapeutics Inc (NASDAQ: Latest Ratings fo.....»»

Roche acquired Spark Therapeutics for a cool $4.8 billion, which sent peers soaring......»»

Brainstorm Health Daily: February 25, 2019 Happy Monday, readers! I hope you enjoyed your weekend. Oh, what a difference a deal (or two) can make. Biotech companies developing gene therapies and gene editing tech saw their shares.....»»

Roche Pays Up To Enter The Gene Therapy Space.....»»

While sales were up, net income shrank for the Bethesda defense giant......»»

In this week’s Petri Dish we’ll take a look at a new Cambridge company founded by gene-editing experts that emerged with some big funding, as well as Foghorn Therapeutics’ new CFO and the awardees of $2.8 million in women's health funding......»»

Tesla has decided to reduce the price of its 'full self-driving' subscription by half to $99 per month. This decision has led Gene Munster, Managing Partner at Deepwater Asset Management, to predict the end of manual driving. read more.....»»

US Domestic Deposits Tumble $60BN As Small Bank Loan Volumes Shrank Most.....»»

Chef Aaron Adams unveils latest plant-based restaurant, a pop-up at Langbaan, and Gene Simmons' Rock & Brews lands in Clark County......»»